![Vera Therapeutics, Inc.](https://s33007.pcdn.co/wp-content/uploads/2021/07/Vera-Therapeutics.jpg)
Vera Therapeutics (the “Company” or “Vera”) is a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The Company’s lead product candidate, atacicept, a self-administered fusion protein that blocks both B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), is currently being evaluated for the treatment of immunoglobulin A nephropathy (IgAN).